- Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysisLu, S.; Cho, B. C.; Lee, J-S.; Lee, S-H.; Danchaivijitr, P.; Liu, B.; Alip, A.; Xiong, H.; How, S. H.; Chang, G-C.; Yang, J. C-H.; Yoshioka, H.; Xia, K.; Martinez, M.; Bauml, J. M.; Sethi, S.; Hayashi, H.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysisZhou, C.; Tang, K.; Liu, B.; Kim, S-W.; Kitazono, S.; Ono, A.; Thiagarajan, M.; Hung, J-Y.; Boyer, M.; Xie, J.; Bhattacharya, A.; Baig, M.; Agrawal, T.; Knoblauch, R. E.; Cho, B. C.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Tepotinib plus osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinibTan, Daniel Shao-Weng; Kim, Tae Min; Guarneri, Valentina; Voon, Pei Jye; Lim, Boon Khaw; Wislez, Marie; Huang, Cheng; Liam, Chong Kin; Mazieres, Julien; Tho, Lye Mun; Hayashi, Hidetoshi; Nhung, Nguyen; Chia, Puey Ling; De Marinis, Filippo; Le, Xiuning; Karachaliou, Niki; Brutlach, Sabine; Adrian, Svenja; Ellers-Lenz, Barbara; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced nonsmall cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial
2被引4阅读
